AR063099A1 - Compuestos y composiciones como inhibidores de la proteina quinasa - Google Patents
Compuestos y composiciones como inhibidores de la proteina quinasaInfo
- Publication number
- AR063099A1 AR063099A1 ARP070104361A ARP070104361A AR063099A1 AR 063099 A1 AR063099 A1 AR 063099A1 AR P070104361 A ARP070104361 A AR P070104361A AR P070104361 A ARP070104361 A AR P070104361A AR 063099 A1 AR063099 A1 AR 063099A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- substituted
- heterocycloalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La invencion proporciona una nueva clase de compuestos inhibidores de proteína quinasa y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos son utiles en el tratamiento o prevencion de enfermedades o trastornos asociados con la actividad anormal o irregular de la quinasa, en especial enfermedades o trastornos en los que ocurre la activacion anormal de las quinasas AbI, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK, Src, Tie2 y TrkB, como en los estados proliferativos benignos o malignos y en enfermedades autoinmunes. 1. Un compuesto de Formula (1) donde: A es un anillo de 5 miembros, insaturado o parcialmente insaturado que contiene 1 a 3 heteroátomos seleccionados entre -N=, - NR3-, -O- y -S-; donde R3 se selecciona entre hidrogeno, halo, alquiloC1-6-halo-sustituido, alquiloC1-6, -XOR4a, -XCN, -XC(O)OR4a, -XC(O)R4b, -XNR4aR4a, -XNR4aXNR4aR4a, -XC(O)NR4aXNR4aR4a, -XC(O)NR4aXR4b, -XC(O)NR4aXNR4aR4b, - XC(O)NR4aXOR4a, - XNR4aXNR4aR4b, -XNR4aXOR4a, -XNR4aXCF3, - XC(O)NR4aR4a, y -XR4b; donde cada X se selecciona independientemente entre un enlace y alquilenoC1-4; R4a se selecciona entre hidrogeno y alquiloC1-6 y R4b se selecciona entre ariIoC6-10, heteroariloC1-10, cicloalquiloC3-10 y heterocicloalquiloC3-10; donde cualquier cicloalquilo, heterocicloalquilo, arilo o heteroarilo de R4b está opcionalmente sustituido con 1 a 3 radicales seleccionados independientemente entre alquiloC1-6 y -NR4R4d; donde cada 4c y 4d se selecciona independientemente entre hidrogeno y alquiloC1-6; con la condicion de que el anillo A no es imidazol; donde cualquier anillo A puede estar opcionalmente sustituido con un radical R3 con la condicion de que R3 no es halo cuando está unido directamente a un átomo de nitrogeno; B es un anillo de 5 o 6 miembros, insaturado o parcialmente insaturado que contiene de 0 a 3 heteroátomos seleccionados entre -N=, -NR21-, -O- y -S-; donde R21 se selecciona entre hidrogeno, alquiloC1-6, alquiloC1-6-halo-sustituido y halo; donde B puede estar opcionalmente sustituido con 1 a 3 radicales seleccionados independientemente entre alquiloC1-6, alquiloC1-6-halo-sustituido y halo; Z se selecciona entre C y N; R1 se selecciona entre -XNR5R6, -XNR5XNR5R6, -XNR5XR5, - XNR5XOR6, -XNR6XC(O)OR5, -XNR6XC(O)NR6R6, -XOR5, -XC(O)R5, -XR5 y -XS(O)0-2R5 donde X se selecciona entre un enlace y alquilenoC1-4 opcionalmente sustituido con 1 a 2 radicales alquiloC1-6; R5 se selecciona entre hidrogeno, alquiloC1-6, arilC6-10-alquiloC0-4, heteroarilC1-10-alquiloC0-4, cicloalquilC3-10-alquiloC0-4 y heterocicloalquilC3-10-alquiloC0-4; y cada R6 se selecciona independientemente entre hidrogeno y alquiloC1-6; o R5 y R6 juntos con el nitrogeno al cual R5 y R6 están ambos unidos forman heteroarilo o heterocicloalquilo; o R1 junto con el N1 del anillo pirimidina al cual R1 está unido forman 2,3-dihidroimidazo[1,2-f]pirimidina; donde cualquier arilo, heteroarilo, cicloalquilo y heterocicloalquilo de R5 o la combinacion de R5 y R6 puede estar opcionalmente sustituido con 1 a 3 radicales seleccionados independientemente entre halo, nitro, ciano, hidroxi, alquiloC1-6, alcoxiC1-6, alquilo-halo-sustituido, alcoxi-halo-sustituido, -XNR7R8, -XOR7, - XNR7S(O)2R8, -XNR7S(O)R8, -XNR7SR8, -XC(O)NR7R8, -XC(O)NR7XNR7R8, XNR7C(O)NR7R8, -XNR7XNR7R8, -XNR7XOR7, -XNR7C(=NR7)NR7R8, -XS(O)2R9, -XNR7C(O)R8, -XNR7C(O)R9, -XR9, -XC(O)OR8, -XS(O)2NR7R8, -XS(O)NR7R8 y -XSNR7R8; donde X es un enlace o alquilenoC1-4; R7 y R8 se seleccionan independientemente del grupo formado por hidrogeno y alquiloC1-4; y R9 se selecciona entre heterocicloalquiloC3-10 y heteroariloC1-10; donde dicho heterocicloalquilo o heteroarilo de R9 está opcionalmente sustituido con un radical seleccionado del formado por alquiloC1-4, -XNR7XNR7R7, XNR7XOR7 y -XOR7; R2 se selecciona entre -R11, -CONR10R11, SO2NR10R11, -NR10R11, -NR10C(O)R11, -NR10S(O)0-2R11 y -NR10C(O)NR10R11; donde R10 se selecciona entre hidrogeno y alquiloC1-6; R11 se selecciona entre ariloC6-10, heteroariloC1-10, cicloaIquiloC3-10 y heterocicloalquiloC3-10; donde cualquier arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R11 está opcionalmente sustituido con 1 a 3 radicales seleccionados entre halo, nitro, ciano, hidroxi, alquiloC1-6, alcoxiC1-6, alquiloC1-6-halo-sustituido, alquiloC1-6-ciano-sustituido, alquiloC1-6-hidroxi- sustituido, alcoxiC1-6-halo-sustituido, -X2R13, -X2NR12C(O)R13, -X2NR12C(O)NR12R13, - X2NR12R12, -X2NR12R13, -X2NR12X2R13, -X2NR12NR12R12, -X2NR12X2OR12, -X2C(O)NR12R13, -X2NR12S(O)0-2R13 y -X2S(O)0-2NR12R13 donde X2 se selecciona entre un enlace, alquilenoC1-4 y alquenilenoC2-4; R12 se selecciona entre hidrogeno, alquiloC1-6 y aIquiloC1-6-hidroxi-sustituido; R13 se selecciona entre ariloC6-10, heteroariloC1-10, cicloalquiloC3-10 y heterocicloalquiloC3-10; donde cualquier arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R13 está opcionalmente sustituido con 1 a 3 radicales seleccionados independientemente entre halo, ciano, hidroxi, nitro, amino, alquiloC1-6, alquiloC1-6-halo-sustituido, alquiloC1-6-hidroxi-sustituido, alquiloC1-6-ciano-sustituido, alquiloC1-6-hidroxi-sustituido, alcoxiC1-6, alcoxiC1-6-halo- sustituido, -X3NR7R8, -X3NR7X3OR7, arilC6-10-alquiloC0-4, heteroarilC1-10-alquiloC0-4, cicloalquilC3-10-alquiloC0-4, heterocicloalquilC3-10-alcoxiC0-4; y heterocicloalquilC3-10-alquiloC0-4; donde X3 se selecciona entre un enlace y alquilenoC1-4; R7 y R8 son como se describieron anteriormente y donde cualquiera de los sustituyentes arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R13 está además opcionalmente sustituido con 1 a 3 radicales seleccionados independientemente entre halo, hidroxi, alquiloC1-6, alquiloC1-6-halo-sustituido, alquiloC1-6-hidroxi-sustituido, aIcoxiC1-6, heterocicloalquiloC3-10 y alcoxiC1-6-halo-sustituido; R20 se selecciona entre hidrogeno y alquiloC1-6 y sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82787306P | 2006-10-02 | 2006-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063099A1 true AR063099A1 (es) | 2008-12-30 |
Family
ID=38955203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104361A AR063099A1 (es) | 2006-10-02 | 2007-10-02 | Compuestos y composiciones como inhibidores de la proteina quinasa |
Country Status (22)
Country | Link |
---|---|
US (1) | US8202876B2 (es) |
EP (1) | EP2057146A1 (es) |
JP (1) | JP5153777B2 (es) |
KR (1) | KR101101675B1 (es) |
CN (2) | CN103739595A (es) |
AR (1) | AR063099A1 (es) |
AU (1) | AU2007305016B2 (es) |
BR (1) | BRPI0719797A8 (es) |
CA (1) | CA2663366C (es) |
CL (1) | CL2007002836A1 (es) |
CO (1) | CO6180440A2 (es) |
CR (1) | CR10670A (es) |
EA (1) | EA015751B1 (es) |
IL (1) | IL197724A0 (es) |
MA (1) | MA30772B1 (es) |
MX (1) | MX2009003456A (es) |
NO (1) | NO20091759L (es) |
PE (1) | PE20080828A1 (es) |
SM (1) | SMAP200900020A (es) |
TN (1) | TN2009000105A1 (es) |
TW (1) | TW200823200A (es) |
WO (1) | WO2008042639A1 (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007328981B2 (en) | 2006-12-08 | 2013-07-11 | F. Hoffmann-La Roche Ag | Substituted pyrimidines and their use as JNK modulators |
US8440832B2 (en) * | 2007-07-13 | 2013-05-14 | Board Of Regents, The University Of Texas System | Heterocyclic modulators of cannabinoid receptors |
US8334301B2 (en) * | 2007-09-28 | 2012-12-18 | Takeda Pharmaceutical Company Limited | 5-Membered heterocyclic compound |
US20110003809A1 (en) * | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
TW200940539A (en) * | 2008-02-29 | 2009-10-01 | Array Biopharma Inc | RAF inhibitor compounds and methods of use thereof |
WO2009111280A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
EP2265608A2 (en) * | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
EP2671891A3 (en) | 2008-06-27 | 2014-03-05 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
MX2011000738A (es) * | 2008-07-24 | 2011-02-23 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoles como inhibidoers de proteina cinasa. |
MX2011012037A (es) * | 2009-05-13 | 2012-02-28 | Amgen Inc | Compuestos de heteroarilo como inhibidores de pikk. |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
CA2855243C (en) | 2011-11-11 | 2020-04-14 | Novartis Ag | Method of treating a proliferative disease |
CN105708819B (zh) | 2011-11-23 | 2020-12-29 | 诺华股份有限公司 | 医药制剂 |
SG10201704095UA (en) * | 2012-04-24 | 2017-06-29 | Vertex Pharma | Dna-pk inhibitors |
PT3176170T (pt) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
CN107200749B (zh) | 2013-03-12 | 2019-09-03 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
PE20152033A1 (es) | 2013-04-19 | 2016-01-21 | Incyte Holdings Corp | Heterociclos bicicliclos como inhibidores de fgfr |
CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
EP3057953B1 (en) | 2013-10-17 | 2018-08-15 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
PT3057959T (pt) * | 2013-10-17 | 2018-06-04 | Vertex Pharma | Inibidores de adn-pk |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
EP3617205B1 (en) | 2015-02-20 | 2021-08-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
WO2016164754A1 (en) * | 2015-04-09 | 2016-10-13 | Eisai R&D Management Co., Ltd. | Fgfr4 inhibitors |
WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US10301255B2 (en) * | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US9890163B2 (en) | 2015-10-15 | 2018-02-13 | Princeton Drug Discovery Inc | Inhibitors of protein kinases |
US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
JP6904970B2 (ja) | 2016-03-07 | 2021-07-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | B型肝炎抗ウイルス剤 |
CN109843296A (zh) | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | 乙型肝炎抗病毒药剂 |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
CN108699039B (zh) * | 2017-01-20 | 2019-12-20 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物 |
US11091462B2 (en) | 2017-01-20 | 2021-08-17 | Shenzhen Targetrx, Inc. | (Hetero)arylamide compound for inhibiting protein kinase activity |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
MX2020002191A (es) | 2017-08-28 | 2020-10-05 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis b. |
US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10428070B2 (en) | 2017-12-06 | 2019-10-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2019141957A1 (en) | 2018-01-19 | 2019-07-25 | Cado Biotechnology Ivs | N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof |
US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
CN112867716A (zh) | 2018-05-04 | 2021-05-28 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
JP2022507724A (ja) | 2018-11-21 | 2022-01-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス剤としての官能化複素環 |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
JOP20220083A1 (ar) | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
WO2022255778A1 (ko) | 2021-06-01 | 2022-12-08 | 주식회사 에즈큐리스 | Il-33 단백질 저해용 화합물의 스크리닝 방법 및 상기 화합물을 포함하는 알러지성 질환 치료용 약학조성물 |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
WO2023158795A1 (en) * | 2022-02-18 | 2023-08-24 | Accent Therapeutics, Inc. | Inhibitors of rna helicase dhx9 and uses thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0178035B1 (en) * | 1984-05-12 | 1990-01-03 | FISONS plc | Anti-inflammatory 1,n-diarylpyrazol-3-amines, compositions containing them and processes for their preparation |
US6979686B1 (en) * | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
US6087381A (en) | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
WO2001030154A2 (de) | 1999-10-25 | 2001-05-03 | Basf Aktiengesellschaft | Pyrazole enthaltende agrochemische zusammensetzungen und ihre verwendung als fungizide flanzenschutzmittel |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
AR042067A1 (es) | 2002-11-27 | 2005-06-08 | Bayer Pharmaceuticals Corp | Derivados de anilinopirazol utiles en el tratamiento de la diabetes |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
CA2534921C (en) * | 2003-08-06 | 2011-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
AU2005205118B2 (en) | 2004-01-09 | 2009-02-26 | Novartis Ag | Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-IR inhibitors |
CN1956982A (zh) * | 2004-05-21 | 2007-05-02 | 万有制药株式会社 | 具有氨基噻唑骨架的Cdk4、6选择性抑制剂 |
TW200610762A (en) * | 2004-06-10 | 2006-04-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
CN101039933B (zh) * | 2004-09-17 | 2012-06-06 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的二氨基三唑化合物 |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
JP2008540674A (ja) | 2005-05-20 | 2008-11-20 | アレイ バイオファーマ、インコーポレイテッド | Raf阻害化合物およびその使用方法 |
DE102005036126A1 (de) | 2005-07-26 | 2007-02-01 | Carl Zeiss Industrielle Messtechnik Gmbh | Sensormodul für einen Tastkopf eines taktilen Koordinatenmessgerätes |
EP1928455A1 (en) * | 2005-08-31 | 2008-06-11 | Bayer Healthcare, LLC | Anilinopyrazole derivatives useful for the treatment of diabetes |
EP1934228A2 (en) | 2005-09-01 | 2008-06-25 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
WO2007105058A2 (en) | 2006-03-16 | 2007-09-20 | Pfizer Products Inc. | Pyrazole compounds |
WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
-
2007
- 2007-09-24 CA CA2663366A patent/CA2663366C/en not_active Expired - Fee Related
- 2007-09-24 JP JP2009531524A patent/JP5153777B2/ja not_active Expired - Fee Related
- 2007-09-24 WO PCT/US2007/079340 patent/WO2008042639A1/en active Search and Examination
- 2007-09-24 KR KR1020097006724A patent/KR101101675B1/ko not_active IP Right Cessation
- 2007-09-24 CN CN201310581142.7A patent/CN103739595A/zh active Pending
- 2007-09-24 BR BRPI0719797A patent/BRPI0719797A8/pt not_active Application Discontinuation
- 2007-09-24 US US12/444,129 patent/US8202876B2/en not_active Expired - Fee Related
- 2007-09-24 CN CNA2007800368577A patent/CN101522661A/zh active Pending
- 2007-09-24 MX MX2009003456A patent/MX2009003456A/es active IP Right Grant
- 2007-09-24 AU AU2007305016A patent/AU2007305016B2/en not_active Ceased
- 2007-09-24 EP EP07814982A patent/EP2057146A1/en not_active Withdrawn
- 2007-09-24 EA EA200970347A patent/EA015751B1/ru not_active IP Right Cessation
- 2007-10-02 PE PE2007001326A patent/PE20080828A1/es not_active Application Discontinuation
- 2007-10-02 CL CL200702836A patent/CL2007002836A1/es unknown
- 2007-10-02 TW TW096136908A patent/TW200823200A/zh unknown
- 2007-10-02 AR ARP070104361A patent/AR063099A1/es unknown
-
2009
- 2009-03-19 IL IL197724A patent/IL197724A0/en unknown
- 2009-03-19 CR CR10670A patent/CR10670A/es not_active Application Discontinuation
- 2009-03-27 SM SM200900020T patent/SMAP200900020A/it unknown
- 2009-03-27 TN TN2009000105A patent/TN2009000105A1/fr unknown
- 2009-04-02 CO CO09034040A patent/CO6180440A2/es not_active Application Discontinuation
- 2009-04-02 MA MA31753A patent/MA30772B1/fr unknown
- 2009-05-04 NO NO20091759A patent/NO20091759L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR101101675B1 (ko) | 2011-12-30 |
NO20091759L (no) | 2009-07-01 |
TN2009000105A1 (en) | 2010-08-19 |
SMAP200900020A (it) | 2009-05-11 |
EA015751B1 (ru) | 2011-12-30 |
CA2663366C (en) | 2012-02-07 |
CN103739595A (zh) | 2014-04-23 |
WO2008042639A1 (en) | 2008-04-10 |
EP2057146A1 (en) | 2009-05-13 |
US20100029605A1 (en) | 2010-02-04 |
TW200823200A (en) | 2008-06-01 |
BRPI0719797A8 (pt) | 2017-12-26 |
AU2007305016A1 (en) | 2008-04-10 |
KR20090060322A (ko) | 2009-06-11 |
PE20080828A1 (es) | 2008-08-12 |
MX2009003456A (es) | 2009-04-14 |
BRPI0719797A2 (pt) | 2017-10-24 |
EA200970347A1 (ru) | 2009-10-30 |
CO6180440A2 (es) | 2010-07-19 |
CN101522661A (zh) | 2009-09-02 |
IL197724A0 (en) | 2009-12-24 |
JP2010505862A (ja) | 2010-02-25 |
AU2007305016B2 (en) | 2011-11-03 |
JP5153777B2 (ja) | 2013-02-27 |
CA2663366A1 (en) | 2008-04-10 |
CR10670A (es) | 2009-05-13 |
MA30772B1 (fr) | 2009-10-01 |
CL2007002836A1 (es) | 2008-05-23 |
US8202876B2 (en) | 2012-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063099A1 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
PE20230161A1 (es) | Inhibidores de proteinas kras mutantes | |
AR049511A1 (es) | Compuestos y composiciones como inhibidores de quinasa de proteina | |
PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
PE20211411A1 (es) | Compuestos de anillo fusionado | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
PE20120107A1 (es) | Inhibidores de proteina cinasa | |
PE20080548A1 (es) | Derivados de [4,5']bipirimidinil-6,4'-diamina como inhibidores de cinasa de proteina | |
PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
PE20190475A1 (es) | Inhibidores de cdk2/4/6 | |
PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
AR080688A1 (es) | Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina | |
AR042042A1 (es) | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular | |
PE20151776A1 (es) | Compuestos de heteroarilo y sus usos | |
PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
AR049319A1 (es) | Derivados de 6-heteroarilfenantridinas | |
AR050365A1 (es) | Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos. | |
PE20150218A1 (es) | Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
AR074499A1 (es) | Carboxamidas heterobiciclicas como inhibidoras de cinasas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |